Prostate Adenocarcinoma Clinical Trial
— NRG PROMETHEANOfficial title:
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Verified date | February 2024 |
Source | NRG Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.
Status | Recruiting |
Enrollment | 260 |
Est. completion date | October 10, 2029 |
Est. primary completion date | October 10, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration - Age = 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 120 days prior to registration - Prior curative-intent treatment to the prostate, by either: - External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites - Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes - Must meet study entry criteria based on the following diagnostic workup within 120 days prior to registration: - History and physical examination; - Technetium TC-99m (99mTc) bone scan (Must be negative); - Either computed tomography (CT) or magnetic resonance imaging (MRI) of pelvis +/- abdomen (Must be negative); - Fluciclovine or prostate-specific membrane antigen (PSMA) PET scan (Must be positive with exception of local disease); - Note: All 3 scans are mandatory (bone scan; CT/magnetic resonance [MR]; PET) - 1 - 5 oligometastatic lesions in bone and/or nodal/soft tissue sites on fluciclovine or PSMA PET within 120 days prior to registration and includes at least ONE of the following: - Bone - each metastasis is counted (for example, 2 distinct lesions in the right ilium count as 2 oligometastatic lesions) - Extrapelvic Nodal/ soft tissue - requires at least one extrapelvic inguinal or a nodal/soft tissue lesion superior to the iliac bifurcation (that is, American Joint Committee on Cancer [AJCC] M1a version 8) - Note: Although a patient must have bone and/or extrapelvic disease to be eligible, when counting the number of oligometastatic lesions, each lymph node lesion, whether pelvic or extrapelvic, is counted (for example, 2 distinct lymph nodes in the right external iliac basin count as 2 oligometastatic lesions; one extrapelvic and one pelvic node count as 2 oligometastic lesions, etc) - Serum total prostate-specific antigen (PSA) =10.0 ng/mL obtained within 120 days prior to registration that also meets ONE of the following PSA recurrence definitions: - PSA = post-radiation therapy (RT) nadir PSA + 2 ng/mL, if patient received-radiation therapy to intact prostate, or - Current PSA = 0.2 ng/mL, with a second confirmatory PSA = 0.2 ng/mL if patient received a radical prostatectomy with or without post-op RT - Must have =3 PSA values within the last two years since end of primary treatment or within the last 2 years prior to registration, whichever is less - Note: PSA doubling time must be calculated by entering all PSA values since end of primary treatment or within the last 2 years prior to registration (whichever is less) into the PSA Doubling Time Calculator found at MDCalc.com - Serum total testosterone = 100 ng/dL within 120 days prior to registration - Note: Prior androgen deprivation therapy (other than bilateral orchiectomy) is allowed if discontinued prior to registration and serum total testosterone is = 100 ng/dL - Total bilirubin: = 1.5 x institutional upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, subject is eligible if direct bilirubin is = 1.5 x ULN) (within 120 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]): = 2.5 x institutional ULN (within 120 days prior to registration) - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial - The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information. Exclusion Criteria: - Clinical, biopsy-proven, or radiologic (conventional or PET imaging) evidence of local tumor recurrence in the prostate and/or periprostatic/seminal vesicle region after radiotherapy, or in the prostate bed after prostatectomy - Note: if a patient had a prior local recurrence and received local salvage therapy, the patient is eligible if there is no current evidence of disease in the prostate/prostate bed. Patients with positive findings on examination or imaging remain eligible if biopsy of the site is negative for cancer. - Currently on androgen deprivation or anti-androgen therapy - Definitive radiologic evidence of metastatic disease on conventional imaging, defined by one of the following: - Osseous metastasis on 99mTc radionuclide bone scan, or - Extra pelvic nodal/soft tissue disease (> 1.5 cm in short axis) on CT or MRI pelvis +/- abdomen - Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver, lung, etc.) metastasis - Note: Spinal metastases (PET-detected) with epidural extension are eligible if there is > 0.3 cm spatial separation between the gross tumor volume and spinal cord. - Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell) - Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for = 3 years - Prior chemotherapy for prostate cancer or bilateral orchiectomy - Note: Prior chemotherapy for a different cancer is allowed if continuously disease-free for = 3 years - Prior radiotherapy to a lesion (i.e. oligometastatic recurrence by PET) - Note: Lesions outside of a previously irradiated planning treatment volume (PTV) are eligible as long as the prescription isovolume dose of any prior radiotherapy course is > 2.0 cm distant from new lesion - Inability to treat all oligometastatic sites with radiotherapy in the judgement of the investigator - Intrapelvic lymph nodes as only site of prostate cancer recurrence - Inability to swallow whole, undivided, unchewed, and uncrushed pills - Known gastrointestinal disorder affecting oral medication absorption - Co-morbidity defined as follows: - Patients with any comorbidities that would prohibit completion of protocol specified therapy - Inflammatory bowel disease in patients in whom abdominopelvic radiotherapy is planned - History of congenital long QT syndrome - Current severe or unstable angina - New York Heart Association functional classification III/IV heart failure (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification) |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | University of New Mexico Cancer Center | Albuquerque | New Mexico |
United States | UPMC Altoona | Altoona | Pennsylvania |
United States | Mary Greeley Medical Center | Ames | Iowa |
United States | McFarland Clinic - Ames | Ames | Iowa |
United States | Saint Joseph Mercy Hospital | Ann Arbor | Michigan |
United States | Langlade Hospital and Cancer Center | Antigo | Wisconsin |
United States | Emory Saint Joseph's Hospital | Atlanta | Georgia |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia |
United States | Grady Health System | Atlanta | Georgia |
United States | Piedmont Hospital | Atlanta | Georgia |
United States | UCHealth University of Colorado Hospital | Aurora | Colorado |
United States | UH Seidman Cancer Center at UH Avon Health Center | Avon | Ohio |
United States | Advocate Good Shepherd Hospital | Barrington | Illinois |
United States | UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio |
United States | UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania |
United States | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California |
United States | Tower Cancer Research Foundation | Beverly Hills | California |
United States | Rocky Mountain Cancer Centers-Boulder | Boulder | Colorado |
United States | Saint Joseph Mercy Brighton | Brighton | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan |
United States | Bryn Mawr Hospital | Bryn Mawr | Pennsylvania |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Saint Joseph Mercy Canton | Canton | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | Carlisle Regional Cancer Center | Carlisle | Pennsylvania |
United States | Miami Valley Hospital South | Centerville | Ohio |
United States | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania |
United States | Chambersburg Hospital | Chambersburg | Pennsylvania |
United States | Saint Joseph Mercy Chelsea | Chelsea | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan |
United States | Advocate Illinois Masonic Medical Center | Chicago | Illinois |
United States | Michigan Healthcare Professionals Clarkston | Clarkston | Michigan |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Memorial Hospital North | Colorado Springs | Colorado |
United States | UCHealth Memorial Hospital Central | Colorado Springs | Colorado |
United States | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri |
United States | AMG Crystal Lake - Oncology | Crystal Lake | Illinois |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Dayton Blood and Cancer Center | Dayton | Ohio |
United States | Miami Valley Hospital | Dayton | Ohio |
United States | Miami Valley Hospital North | Dayton | Ohio |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Iowa Methodist Medical Center | Des Moines | Iowa |
United States | Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa |
United States | Fox Chase Cancer Center - East Norriton Hospital Outpatient Center | East Norriton | Pennsylvania |
United States | Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | Advocate Sherman Hospital | Elgin | Illinois |
United States | UPMC Hillman Cancer Center Erie | Erie | Pennsylvania |
United States | Sanford Broadway Medical Center | Fargo | North Dakota |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Michigan Healthcare Professionals Farmington | Farmington Hills | Michigan |
United States | UPMC Cancer Center at UPMC Horizon | Farrell | Pennsylvania |
United States | Piedmont Fayette Hospital | Fayetteville | Georgia |
United States | Cancer Care and Hematology-Fort Collins | Fort Collins | Colorado |
United States | Poudre Valley Hospital | Fort Collins | Colorado |
United States | Parkview Regional Medical Center | Fort Wayne | Indiana |
United States | Beebe South Coastal Health Campus | Frankford | Delaware |
United States | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio |
United States | Fox Chase Cancer Center Buckingham | Furlong | Pennsylvania |
United States | Aurora Cancer Care-Grafton | Grafton | Wisconsin |
United States | UCHealth Greeley Hospital | Greeley | Colorado |
United States | Aurora BayCare Medical Center | Green Bay | Wisconsin |
United States | East Carolina University | Greenville | North Carolina |
United States | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania |
United States | Advocate South Suburban Hospital | Hazel Crest | Illinois |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | UCHealth Highlands Ranch Hospital | Highlands Ranch | Colorado |
United States | Edwards Comprehensive Cancer Center | Huntington | West Virginia |
United States | IRMC Cancer Center | Indiana | Pennsylvania |
United States | Jupiter Medical Center | Jupiter | Florida |
United States | GenesisCare USA - Lakewood Ranch | Lakewood Ranch | Florida |
United States | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon | New Hampshire |
United States | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania |
United States | AMG Libertyville - Oncology | Libertyville | Illinois |
United States | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan |
United States | Cedars Sinai Medical Center | Los Angeles | California |
United States | Los Angeles General Medical Center | Los Angeles | California |
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Medical Center of the Rockies | Loveland | Colorado |
United States | Covenant Medical Center-Lakeside | Lubbock | Texas |
United States | Michigan Healthcare Professionals Macomb | Macomb | Michigan |
United States | Michigan Healthcare Professionals Madison Heights | Madison Heights | Michigan |
United States | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin |
United States | Marshfield Medical Center-Marshfield | Marshfield | Wisconsin |
United States | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg | Pennsylvania |
United States | Riddle Memorial Hospital | Media | Pennsylvania |
United States | Froedtert Menomonee Falls Hospital | Menomonee Falls | Wisconsin |
United States | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor | Ohio |
United States | East Jefferson General Hospital | Metairie | Louisiana |
United States | LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie | Louisiana |
United States | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin |
United States | Aurora Sinai Medical Center | Milwaukee | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin |
United States | Memorial Medical Center | Modesto | California |
United States | UPMC Hillman Cancer Center in Coraopolis | Moon | Pennsylvania |
United States | ProHealth D N Greenwald Center | Mukwonago | Wisconsin |
United States | Carolina Regional Cancer Center | Myrtle Beach | South Carolina |
United States | Cancer Center of Western Wisconsin | New Richmond | Wisconsin |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Medical Oncology Hematology Consultants PA | Newark | Delaware |
United States | Drexel Town Square Health Center | Oak Creek | Wisconsin |
United States | Advocate Christ Medical Center | Oak Lawn | Illinois |
United States | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California |
United States | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin |
United States | Paoli Memorial Hospital | Paoli | Pennsylvania |
United States | The Valley Hospital-Luckow Pavilion | Paramus | New Jersey |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | University Hospitals Parma Medical Center | Parma | Ohio |
United States | Methodist Medical Center of Illinois | Peoria | Illinois |
United States | OSF Saint Francis Medical Center | Peoria | Illinois |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Cancer Center at Saint Joseph's | Phoenix | Arizona |
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | UPMC-Magee Womens Hospital | Pittsburgh | Pennsylvania |
United States | UPMC-Passavant Hospital | Pittsburgh | Pennsylvania |
United States | UPMC-Saint Margaret | Pittsburgh | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | GenesisCare USA - Plantation | Plantation | Florida |
United States | Saint Joseph Mercy Oakland | Pontiac | Michigan |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Geisinger Cancer Services-Pottsville | Pottsville | Pennsylvania |
United States | University Hospitals Portage Medical Center | Ravenna | Ohio |
United States | Beebe Health Campus | Rehoboth Beach | Delaware |
United States | Ascension Saint Mary's Hospital | Rhinelander | Wisconsin |
United States | Highland Hospital | Rochester | New York |
United States | University of Rochester | Rochester | New York |
United States | Delbert Day Cancer Institute at PCRMC | Rolla | Missouri |
United States | William Beaumont Hospital-Royal Oak | Royal Oak | Michigan |
United States | Norris Cotton Cancer Center-North | Saint Johnsbury | Vermont |
United States | Siteman Cancer Center at Christian Hospital | Saint Louis | Missouri |
United States | Siteman Cancer Center-South County | Saint Louis | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri |
United States | UPMC Cancer Center at UPMC Northwest | Seneca | Pennsylvania |
United States | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin |
United States | Memorial Hospital East | Shiloh | Illinois |
United States | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Ascension Saint Michael's Hospital | Stevens Point | Wisconsin |
United States | Marshfield Medical Center-River Region at Stevens Point | Stevens Point | Wisconsin |
United States | Aurora Medical Center in Summit | Summit | Wisconsin |
United States | ProMedica Flower Hospital | Sylvania | Ohio |
United States | GenesisCare USA - Troy | Troy | Michigan |
United States | Upper Valley Medical Center | Troy | Ohio |
United States | William Beaumont Hospital - Troy | Troy | Michigan |
United States | UPMC Washington Hospital Radiation Oncology | Washington | Pennsylvania |
United States | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin |
United States | Aspirus Regional Cancer Center | Wausau | Wisconsin |
United States | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin |
United States | Wilmot Cancer Institute at Webster | Webster | New York |
United States | Aurora West Allis Medical Center | West Allis | Wisconsin |
United States | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Wisconsin |
United States | Marshfield Medical Center - Weston | Weston | Wisconsin |
United States | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania |
United States | Divine Providence Hospital | Williamsport | Pennsylvania |
United States | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids | Wisconsin |
United States | Lankenau Medical Center | Wynnewood | Pennsylvania |
United States | UPMC Memorial | York | Pennsylvania |
United States | WellSpan Health-York Cancer Center | York | Pennsylvania |
United States | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
NRG Oncology | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiological progression-free survival (rPFS) | The rPFS curves will be estimated by the Kaplan-Meier method and compared between the two treatment arms using a one-sided, logrank test stratified by the three randomization factors. | Time from randomization to the occurrence of radiological progression detected by conventional imaging or death from any cause, assessed up to 5 years | |
Secondary | Positron emission tomography (PET)-based radiological progression-free survival | Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. | Time from randomization to the occurrence of conventional or PET-based radiological progression or death from any cause, assessed up to 5 years | |
Secondary | Metastasis-free Survival | Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. | From randomization to distant metastases or death from any cause, assessed up to 5 years | |
Secondary | Overall Survival | Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. | From randomization to death from any cause, assessed up to 5 years | |
Secondary | Sexual Function | Assessed by Expanded Prostate Cancer Index Composite Short Form (EPIC-26). | Up to 5 years | |
Secondary | Fatigue | Assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue short form. Longitudinal profiles will be compared using mixed effects regression. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03796767 -
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT05735223 -
A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence
|
N/A | |
Recruiting |
NCT04175431 -
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
|
Phase 2 | |
Completed |
NCT05197257 -
68Ga-PSMA-11 PET in Patients With Prostate Cancer
|
Phase 3 | |
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT02254746 -
A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05496959 -
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
|
Phase 2 | |
Completed |
NCT02940262 -
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
|
Phase 3 | |
Recruiting |
NCT04391556 -
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT03503643 -
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
|
||
Recruiting |
NCT05832086 -
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
|
Phase 2 | |
Suspended |
NCT05064111 -
Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
|
||
Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT02600156 -
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
|
N/A | |
Recruiting |
NCT05726292 -
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04423211 -
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
|
Phase 3 | |
Terminated |
NCT03718338 -
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
|
||
Terminated |
NCT02564549 -
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
|
N/A |